Endo-ERN
  • Members
  • Newsletter
English
  • Български(bg)
  • Čeština(cs)
  • Español(es)
  • Magyar(hu)
  • Italiano(it)
  • polski(pl)
  • Português(pt)
  • Română(ro)
  • Professionals
  • News
  • Events
  • Contact
  • ERN
  • FAQ
  • About
    • About ERN
    • About Endo-ERN
    • Governance
    • Reference Centres
    • ERN Information Materials
  • Specific Expertise
    • Overview
    • Adrenal (MTG1)
    • Disorders of Calcium &
      Phosphate Homeostasis (MTG2)
    • Genetic Disorders of Glucose &
      Insulin Homeostasis (MTG3)
    • Genetic Endocrine
      Tumour Syndromes (MTG4)
    • Growth &
      Genetic Obesity Syndromes (MTG5)
    • Hypothalamic and Pituitary Conditions (MTG6)
    • Sex Development &
      Maturation (MTG7)
    • Thyroid (MTG8)
  • Patients
    • Introduction
    • European Patient Advocacy Group
    • How to Become an Endo-ERN patient representative
    • Endo-ERN Patient Representatives
    • Conditions
    • Cross-border Healthcare
    • Patient information materials
  • Activities
    • Knowledge Generation
    • Research Activities
    • Clinical Activities & eHealth
    • Clinical Trials
    • Endo-ERN Studies
    • ERN Exchange Programme
    • Guidelines
    • Evaluation
    • Other Projects
  • Publications
  • Evaluation
    • Overview
    • Continuous Monitoring Programme
    • 5-Year Evaluation
    • Patient Resources
    • AMEQUIS
Logo Navbar
  • About
    • About
      European Reference Network on Rare Endocrine Conditions mission is to reduce and ultimately abolish inequalities in care for patients with rare endocrine conditions in Europe, through facilitating knowledge sharing and facilitating related healthcare en research.
    • About ERN
    • About Endo-ERN
    • Governance
    • Reference Centres
    • ERN Information Materials
  • Specific Expertise
    • Specific Expertise
      According to usual classification of endocrine conditions, specific diagnostic and therapeutic approaches and composition of the required multidisciplenary teams, eight established Main Thematic Groups (MTGs) were defined within Endo-ERN.
    • Overview
    • Adrenal (MTG1)
    • Disorders of Calcium &
      Phosphate Homeostasis (MTG2)
    • Genetic Disorders of Glucose &
      Insulin Homeostasis (MTG3)
    • Genetic Endocrine
      Tumour Syndromes (MTG4)
    • Growth &
      Genetic Obesity Syndromes (MTG5)
    • Hypothalamic and Pituitary Conditions (MTG6)
    • Sex Development &
      Maturation (MTG7)
    • Thyroid (MTG8)
  • Patients
    • Patients
      Adequate patient representation and coverage of all expertise, and preferably also of the Work-Packages across all member states is top-priority for Endo-ERN. Patients are represented in the Steering Committee to ensure active patient involvement in any strategic decision and action.
    • Introduction
    • European Patient Advocacy Group
    • How to Become an Endo-ERN patient representative
    • Endo-ERN Patient Representatives
    • Conditions
    • Cross-border Healthcare
    • Patient information materials
  • Activities
    • Activities
      Endo-ERN activities are defined in five work packages throughout different phases.
    • Knowledge Generation
    • Research Activities
    • Clinical Activities & eHealth
    • Clinical Trials
    • Endo-ERN Studies
    • ERN Exchange Programme
    • Guidelines
    • Evaluation
    • Other Projects
  • Publications
  • Evaluation
    • Evaluation
      The objective of the European Reference Networks is to ensure accessible diagnosis and treatment for rare diseases. This care should be consistent across the EU/EEA and rare disease type.
    • Overview
    • Continuous Monitoring Programme
    • 5-Year Evaluation
    • Patient Resources
    • AMEQUIS
  • ⁄
  • Activities
  • ⁄
  • Evaluation
  • ⁄
  • AMEQUIS
  • Overview
  • Continuous Monitoring Programme
  • 5-Year Evaluation
  • Patient Resources
  • AMEQUIS

AMEQUIS

AMEQUIS

logo-eurordis
To create a sustainable cycle of improvement, Endo-ERN will in future follow the protocols of the Assessment, Monitoring, Evaluation, and Quality Improvement System (AMEQUIS). It is imperative to monitor the contributions offered to medical care, as well as the conduct of our ERN members, to facilitate the best possible care for rare endocrine disease patients in Europe.

AMEQUIS leaflet (, pdf)

AMEQUIS video (YouTube)

This page is also available in: bg|cs|es|hu|it|pl|pt|ro
Endo-ERN
Coordinating Center
Meibergdreef 9
1105 AZ  AMSTERDAM
The Netherlands
 info@endo-ern.eu
 LinkedIn
 Twitter
 YouTube
 Facebook
Logo EU commmission
Logo ERN
Endo-ERN is funded by the European Union’s Health Programme.

Quick Menu

  • Home
  • Contact
  • Newsletter
  • Frequently Asked Questions
  • Privacy
  • Downloads
© 2016 - 2023  Endo-ERN
Designed by: FeekDesign
Go to top